PPARγ agonists have been noted to possess the therapeutic potential to prevent the development of DN by decreasing the TGF-β (18), by down regulating the expression of glomerular fibronectin and inhibiting ROS in glomeruli of diabetic mice (19) and by suppressing the expression of TGF-β, VEGF, PAI-1, type-IV collagen and ICAM-1 in the kidneys of diabetic rats (20). The gene discussed is TGFB1; the disease is liver dysplastic nodule.